Yonsei Med J.  2009 Feb;50(1):50-54. 10.3349/ymj.2009.50.1.50.

An Outbreak of Oropharyngeal Tularemia with Cervical Adenopathy Predominantly in the Left Side

• Sencan I
• Sahin I
• Kaya D
• Oksuz S
• Ozdemir D
• Karabay O

• KMID: 1782967
• DOI: http://doi.org/10.3349/ymj.2009.50.1.50

Abstract

PURPOSE
We describe the epidemiological and clinical characteristics and the efficacy of a delayed initiation to therapy in an oropharyngeal tularemia outbreak in Duzce, Turkey.
MATERIALS AND METHODS
Between March and June 2000, 22 patients with tularemia were diagnosed by microagglutination tests.
RESULTS
Oropharyngeal and ulceroglandular forms of the disease were discovered. Most of the cases were oropharyngeal (19 cases). The most common symptoms were sore throat (95.4%) and fever (90.9%). Lymphadenopathy (95.4%) and pharyngeal hyperemia (81.8%) were usually observed signs. The lymphadenopathies were localized especially in the left cervical region (66.7%), a finding that has not been previously reported in the literature. The time between the onset of the symptoms and diagnosis was 40.7 +/- 22.8 (10 - 90) days. The patients were treated with streptomycin plus doxycycline and ciprofloxacin. The patients' recoveries took up to 120 days.
CONCLUSION
This report describes the first outbreak of tularemia in northwest Turkey. Tularemia may occur in any region where appropriate epidemiological conditions are found and should be kept in mind for differential diagnosis in oropharyngeal symptoms. Late initiation of therapy may delay complete recovery. In this outbreak, cervical lymph nodes predominantly localized on the 1eft side were found, which had not been previously reported.

Keyword

Outbreak; tularemia; waterborne; oropharyngeal; left cervical lymph nodes

MeSH Terms

Adolescent
Adult
Aged
Child
Diagnosis, Differential
Disease Outbreaks/*statistics & numerical data
Female
Humans
Lymph Nodes/pathology
Lymphatic Diseases/*microbiology/*pathology
Male
Middle Aged
Oropharynx
Tularemia/*epidemiology/*pathology
Turkey/epidemiology
Water
Young Adult

Reference

1. Jacobs RF. Fauci AS, Braunwald F, Isselbach RJ, Wilson JD, Martin JB, Kasper DL, et al. Tularemia. Harrison's principles of internal medicine. 1998. New York: McGraw-Hill;971–975.

2. Maranan MC, Schiff D, Johnson DC, Abrahams C, Wylam M, Gerber SI. Pneumonic tularemia in a patient with chronic granulomatous disease. Clin Infect Dis. 1997. 25:630–633.

3. Byrd RP Jr, Vasquez J, Roy TM. Respiratory manifestation of tick-borne diseases in the Southeastern United States. South Med J. 1997. 90:1–4.

4. Berdal BP, Mehl R, Haaheim H, Løksa M, Grunow R, Buran S, et al. Field detection of Francisella tularensis. Scand J Infect Dis. 2000. 32:287–291.

5. Reintjes R, Dedushaj I, Gjini A, Jorgensen TR, Cotter B, Lieftucht A, et al. Tularemia outbreak investigation in Kosovo: case control and environmental studies. Emerg Infect Dis. 2002. 8:69–73.

6. Tärnvik A, Sandström G, Sjöstedt A. Infrequent manifestations of tularaemia in Sweden. Scand J Infect Dis. 1997. 29:443–446.

7. Penn RL. Mandell GL, Bennett JE, Dolin R, editors. Francisella tularensis (Tularemia). Mandell, Douglas and Bennett's principles and practice of infectious diseases. 1995. 4th ed. New York: Churchill Ligingstone;2060–2068.

8. Syrjälä H, Kujala P, Myllylä V, Salminen A. Airborne transmission of tularemia in farmers. Scand J Infect Dis. 1985. 17:371–375.

9. de la Puente-Redondo VA, del Blanco NG, Gutiérrez-Martín CB, García-Peña FJ, Rodríguez Ferri EF. Comparison of different PCR approaches for typing of Francisella tularensis strains. J Clin Microbiol. 2000. 38:1016–1022.

10. Sato T, Fujita H, Ohara Y, Homma M. Microagglutination test for early specific serodiagnosis of tularemia. J Clin Microbiol. 1990. 28:2372–2374.

11. Enderlin G, Morales L, Jacobs RF, Cross JT. Streptomycin and alternative agents for the treatment of tularemia: review of the literature. Clin Infect Dis. 1994. 19:42–47.

12. Baker CN, Hollis DG, Thornsberry C. Antimicrobial susceptibility testing of Francisella tularensis with a modified Mueller-Hinton broth. J Clin Microbiol. 1985. 22:212–215.

13. Akdiş AC, Kiliçturgay K, Helvaci S, Mistik R, Oral B. Immunological evaluation of erythema nodosum in tularaemia. Br J Dermatol. 1993. 129:275–279.

14. Pérez-Castrillón JL, Bachiller-Luque P, Martín-Luquero M, Mena-Marbín FJ, Herreros V. Tularemia epidemic in northwestern Spain: clinical description and therapeutic response. Clin Infect Dis. 2001. 33:573–576.

15. Taylor JP, Istre GR, McChesney TC, Satalowich FT, Parker RL, McFarland LM. Epidemiologic characteristics of human tularemia in the southwest-central states, 1981-1987. Am J Epidemiol. 1999. 133:1032–1038.

16. Christenson B. An outbreak of tularemia in the northern part of central Sweden. Scand J Infect Dis. 1984. 16:285–290.

17. Helvaci S, Gedikoğlu S, Akalin H, Oral HB. Tularemia in Bursa, Turkey: 205 cases in ten years. Eur J Epidemiol. 2000. 16:271–276.

18. Ohara Y, Sato T, Fujita H, Ueno T, Homma M. Clinical manifestations of tularemia in Japan-analysis of 1,355 cases observed between 1924 and 1987. Infection. 1991. 19:14–17.

19. Syrjälä H, Schildt R, Räisäinen S. In vitro susceptibility of Francisella tularensis to fluoroquinolones and treatment of tularemia with norfloxacin and ciprofloxacin. Eur J Clin Microbiol Infect Dis. 1991. 10:68–70.